By Iain Gilbert
Date: Tuesday 18 Sep 2018
(Sharecast News) - Viking Therapeutics soared as much as 120% in early trading after the firm revealed a positive set of results from a mid-stage trial of its non-alcoholic fatty liver disease treatment.
No recent information was found.
Currency | US Dollars |
Share Price | $ 26.07 |
Change Today | $ 0.41 |
% Change | 1.60 % |
52 Week High | $78.03 |
52 Week Low | $21.28 |
Volume | 8,224,475 |
Shares Issued | 72.03m |
Market Cap | $1,877.76m |
RiskGrade | 326 |
Strong Buy | 7 |
Buy | 10 |
Neutral | 2 |
Sell | 0 |
Strong Sell | 0 |
Total | 19 |
Time | Volume / Share Price |
14:49 | 100 @ $26.07 |
14:49 | 150 @ $26.06 |
14:49 | 314 @ $26.06 |
14:49 | 250 @ $26.08 |
14:49 | 100 @ $26.06 |
You are here: research